Avidity Biosciences: Cofactor Genomics Launches OncoPrism-NSCLC Diagnostic for Lung Cancer Treatment Insights

Cofactor Genomics Launches Groundbreaking Diagnostic Tool for Non-Small Cell Lung Cancer

Cofactor Genomics, Inc., a pioneer in RNA-based precision medicine, recently announces the launch of its novel diagnostic tool, OncoPrism®-NSCLC, designed specifically to predict patient responses to immune checkpoint inhibitors (ICI) for non-small cell lung cancer (NSCLC). This significant development follows the recent Medicare coverage approval for Cofactor's OncoPrism-HNSCC test, underscoring the company's commitment to expanding access to cutting-edge diagnostics for patients battling cancer. Dr. Jarret Glasscock, CEO of Cofactor, emphasizes that this launch is particularly crucial as NSCLC patients represent the largest cohort receiving ICI treatments, highlighting the urgent need for tailored therapeutic strategies in this population.

The OncoPrism-NSCLC test is predicated on pre-treatment tumor biopsies and is performed in Cofactor's CAP-accredited and CLIA-certified laboratory, ensuring high standards of quality and reliability. The validation of this new diagnostic tool is derived from the PREDAPT clinical trial, which encompasses participation from 12 clinical sites and continues to expand with 17 sites involved in the ongoing NSCLC study. Notably, the predictive capabilities of OncoPrism-NSCLC demonstrate a strong correlation with patient responses to both single-agent ICI therapies and regimens combining ICI with chemotherapy, providing oncologists with essential insights to optimize treatment plans.

Cofactor's broader ambitions in oncology are evident as the PREDAPT trial evaluates the OncoPrism platform across a diverse array of cancer types, including colorectal, breast, and bladder cancers, in addition to NSCLC and head and neck squamous cell carcinoma. Through these innovative approaches, Cofactor Genomics aims to address major healthcare challenges and enhance the understanding of RNA's role in medicine. The company's patented Health Expression Models (HEMs) continue to gain recognition in leading medical publications and collaborations with 38 healthcare systems, which represent 20% of the US healthcare landscape. This strategic positioning of the OncoPrism platform, validated by CAP/CLIA and Medicare approval, signifies a transformative step in cancer diagnostics.

As the landscape of cancer treatment evolves, the launch of OncoPrism-NSCLC by Cofactor Genomics represents a critical advancement in personalized medicine. By leveraging RNA-based diagnostics, the company not only enhances patient care but also contributes to the growing body of research aimed at improving treatment outcomes for a variety of malignancies. With its ongoing commitment to innovation and collaboration, Cofactor is poised to make significant strides in the field of oncology.